Supplementary Tables S1, S2 and Figures S1-S5 from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Fig S1 Study Flowchart Fig S2 PIK3CA somatic mutation pattern Fig S3 Lack of apoptotic effect by anastrozole monotherapy (C1D1) and in combination with MK-2206 (C1D17 and surgery) Fig S4 CDH1 somatic mutation pattern Fig S5 ESR1 somatic mutation pattern
Authors: Cynthia X. Ma, Vera Suman, Matthew P. Goetz, Donald Northfelt, Mark E. Burkard, Foluso Ademuyiwa, Michael Naughton, Julie Margenthaler, Rebecca Aft, Richard Gray, Amye Tevaarwerk, Lee Wilke, Tufia Haddad, Timothy Moynihan, Charles Loprinzi, Tina Hieken, Erica K. Barnell, Zachary L. Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B. Wisinski, Elaine Mardis, Ian S. Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L. Griffith, Malachi Griffith, Laurence Doyle, Charles Erlichman, Matthew J. Ellis
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361921222